CRO Sarah Cannon Research Institute has acquired Connecticut's Clinical Development Group, a trial consulting outfit with a wide range of offerings in oncology R&D.
Through the deal, SCRI expects to expand its capabilities in clinical trial planning, project management, regulatory compliance and access to therapeutic expertise, the company said. CDG's years of cancer development work and deep-seated relationships in industry and academia will help SCRI stretch its footprint in the space, CEO Dee Anna Smith said.
"The addition of CDG is an important step for SCRI, as we continue to experience rapid growth in the management and oversight of clinical trials," Smith said in a statement. "CDG's strong passion and dedication to oncology research aligns with our values, and we are excited to add these talented members to our team."
Much of CDG's might will fold into SCRI's Development Innovations segment, the company said, and the acquisition gives SCRI a home base in the biotech hub of Cambridge, MA.
Over the summer, SCRI's capabilities in oncology were enough to lure pharma giant AstraZeneca ($AZN), which signed a deal tasking the institute with identifying biomarkers for certain cancers and selecting patients for clinical trials.
- read the statement